My HPRA: Register

The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Zirtek Plus Decongestant 5mg/120mg Prolonged Release Tablet



UCB (Pharma) Ireland LimitedPA0891/008/001

Main Information

Trade NameZirtek Plus Decongestant 5mg/120mg Prolonged Release Tablet
Active SubstancesPSEUDOEPHEDRINE HYDROCHLORIDE
Cetirizine dihydrochloride
Dosage FormProlonged-release tablet
Licence HolderUCB (Pharma) Ireland Limited
Licence NumberPA0891/008/001

Group Information

ATC CodeR01BA Sympathomimetics
R01BA52 pseudoephedrine, combinations

Status

License statusAuthorised
Licence Issued30/06/2006
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of LicenceProduct not subject to medical prescription in pack sizes up to 10 tablets. Product subject to prescription for pack sizes greater than 10 tablets. Promotion to the public subject to the following restrictions: maximum strength: 10mg, maximum pack size: 10, maximum daily dose: 10mg Promotion to healthcare professionals only for pack sizes greater than 10 tablets.
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back
Follow medicine

Print